None

Hydroxychloroquine fails to modify HIV in patients not taking ART

The use of hydroxychloroquine does not reduce CD8 cell activation in HIV-infected patients not taking antiretroviral therapy, research shows.

Effects of Hydroxychloroquine on Immune Activation and Disease Progression Among HIV-Infected Patients Not Receiving Antiretroviral Therapy A Randomized Controlled Trial Hydroxychloroquine and Immune Activation in HIV

ContextTherapies to decrease immune activation might be of benefit in slowing HIV disease progression.ObjectiveTo determine whether hydroxychloroquine decreases immune activation and slows CD4 cell de...

Probability of long-term glioblastoma survival assessed

(HealthDay) -- Although the overall mortality rate of glioblastoma is high, compared with patients newly diagnosed with glioblastoma, those who survive two years or more after diagnosis have a favorab...

[Comment] Glioblastoma therapy in the elderly: one age does not fit all

The incidence of glioblastoma rises with increasing age, and peaks in the age group 75–84 years. The median age at diagnosis of glioblastoma is currently 64 years, but as life expectancy lengthens a...

NovoTTF Therapy Comparable to Chemotherapy for Glioblastoma Multiforme

NovoTTF™ therapy was comparable to active chemotherapy in extending overall survival in patients with glioblastoma multiforme, with minimal side effects and much better quality of life, according to...

Hydroxychloroquine: Phase I data

Sensitivity To Potential Glioblastoma Treatment Affected By Modification Of Tumor Suppressor

Despite years of research, glioblastoma, the most common and deadly brain cancer in adults, continues to outsmart treatments targeted to inhibit tumor growth. Biologists and oncologists have long unde...

Modification of tumor suppressor affects sensitivity to potential glioblastoma treatment

Despite years of research, glioblastoma, the most common and deadly brain cancer in adults, continues to outsmart treatments targeted to inhibit tumor growth. Biologists and oncologists have long unde...

Clinical and Pharmacogenetic Influences on Response to Hydroxychloroquine in Discoid Lupus Erythematosus: A Retrospective Cohort Study.

The recommended systemic therapy of choice for discoid lupus erythematosus (DLE) is the 4-aminoquinolone antimalarial hydroxychloroquine. There is limited published information on the likelihood of cl...

Clinical characteristics of hydroxychloroquine retinopathy.

Aims To assess the characteristics and outcomes of patients with hydroxychloroquine retinopathy and to review the current screening guidelines. Methods Retrospective chart review of patients diagnosed...

Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry.

A novel and specific liquid chromatography-tandem mass spectrometric method (LC-MS/MS) was developed and validated for the quantification of hydroxychloroquine in human blood using its stable labeled...

Hydroxychloroquine during pregnancy: a review of retinal toxicity in the newborns.

Objective. The objective of this study is to review the published data on ocular toxicity in newborns after in utero exposure to hydroxychloroquine. Methods. All publications related ophthalmologic fo...

Clodronate and hydroxychloroquine in erosive osteoarthritis: a 24-month open randomized pilot study.

We evaluated the efficacy of clodronate for treating active erosive osteoarthritis of the hand and to compare it with hydroxychloroquine. Group A consisted of 24 patients treated for 24 months with c...